Zdrowie i gospodarka · 19/01/2018

FDA Releases Guidance on Compounded Drug Products Under Section 503A of the FD&C Act

The FDA has announced a new guidance for industry regarding compounded drug products that are essentially copies of commercially available drugs, outlining policies for exemptions under Section 503A of the Federal Food, Drug, and Cosmetic Act.